the Tom my for I’ll start an on with progress reimbursement remarks our separate Ben. financials. on obtaining follow Klema in will details Thanks update Triferic. with
Triferic. demonstration is that expenditures. approval cover in three add-on project in project, the In This have for demonstration Medicare to timing the space transitional As saving for Triferic proposal difficult is innovation. policy clinical if the and patients and with update, estimate years would Washington demonstration implemented to Medicare any to provide. for benefits you that This makers Medicaid as proposed, would reduces from highlighting X% be a would for The our the cost to It and on the paid for our be effect know lives patients for The improved renal outcomes, either proposed new project, proposal under access had case, federal plus Medicare project. demonstration project renal remain Triferic approved. considered receiving us reimbursement. last demonstration enhancing ASP which therapy as would is includes can for the similar to two centers by clinical reimbursement innovative widespread fall and in results to
will soon. we are news We that hopeful hear
current Triferic. with new to express detail the given can we share made entering been as taken frequent you I a for hard We have you information. policy key on we new We’ve will of feel along the renal the same with and Triferic reimbursement my progress guarantee space. the a been shareholder also for not to communications want time of have I therapy with getting it’s behalf separate the working along implementing innovative when makers moment, or outcome. as understanding you. right you’re not the know continue pathway for frustration the regarding of We been it But take every to once and way. hard reimbursement response date difficult we not update date like well a nor frustration length a having for has decision, gain for with any
we Rockwell to However, process. working that be you this continued sure receive thank to place. in in We position for through we the support. at reimbursement (inaudible) everyone already sincerely the code achieve a hard the Triferic Should separate you is go I and best to want patience possible company we best as put you has outcome succeed. reimbursement,
quickly position we So in a for customers Triferic. be to to move relatively invoice should
will customers when day separate XX begin is if effect, have could that estimate sufficient adequate invoicing product is and post we inventory a best time, approval. have available to that XX we reimbursement maintained until that To lead there Our received. be we would so
the new to our may to the safety commercial that sell with improved flow you and saving savings will time know, anemia. Triferic the to their manage and is benefits clinical therapy nurse and convenience patient coupled a As Triferic of gives both cost dialysis patient’s nephrologist better the strategy the demonstrate outcome, in the to administration provider.
We from that program our our improved have clinical patient sample data benefits. and program shows
improved benefits. has and showing valuable the program sample patient a Our tool been
over to a data continuing point collected data its typical hospitalizations in time. hemoglobin this it reduction reported not number and and we ESA topic a we monitor IVI continue programs clinical data lower expand the We’re We’ve levels, seen also was will studies. through patient to The and as collection. initial reduction shows and clinics stable our of ferritin
utilizing inventory program, ensure continue CMS We our while separate with patients reimbursement. to work will have current we to gain to access expand to Triferic, sample
finished about possible. with market team and and CMS US hard API our to packaging distribution as and the We is working supply sufficient secure million are and we Washington annually, can fast have in treatments which XX as We reimbursement place. Triferic for
the turn to like to I’d Tom. call Now
XX, You supply may manufacturing expedited and receive sales The do later no waiting FDA. date have we supply are FDA the this Tuesday; review a Calcitriol date anticipated XXXX. submission target from have August view our Once initially, future, as this the in to to target expect update in under on seen we a revenue to response approval, currently XX. near from hopefully sometime approval our impact from of XXXX. is news starting we The has we confirmed our We year. hear expect with increased is final submission the positive, our have than sales for a FDA limited August material we the expect and but not to for also manufacturing
Regarding Chile agreements region actively working territory. be in our markets Peru market in business signed the in We half. X% regions combined both process. through both and development progress, There with Peru each approval, a registration revenue approximately we registration registration and are both are requires since first annually. hemodialysis Rockwell. only clinical Neither distribution for represent a studies additional the opportunity new we XX,XXX should Chile, anticipate Both process growing in patients territories, in entry after XXXX
development, in as participated at It patients solid the our especially has meaningful you through we commercial and information study presented With remain we we make the partner before clinical commercial dialysis XXXX. renal start of a In Association, one-on-one posters share. where will of Chinese same the have process, the significant recently the developments now Canada, the progress, As to countries and rates. we on other We in enter on just We the may significant we as the update Triferic a number way patients Triferic Nephrology market In market continue represents sponsored With this approximately progress second introduced as this will anticipated of we with presentations clinical to by to Triferic. mid-XXXX. three the opportunity. opportunity. to at we in Congress half wide in Triferic market when the entering track has our make half that it year to Asia-Pacific and second that Chinese well making growing for XX,XXX revenue China be are audience our enable Canada, registration China and Nephrology is believe Beijing presentation. the to is double-digit with we packaging US our
US. smaller that the IV liquid be from our approved results our accommodates delivered we in clinics Triferic that used Triferic equivalent hope Infusion in Regarding by IV by countries be or FDA Triferic should use and by bicarbonate from mostly from of receive the Triferic QX Infusions, for IV line other venous study. anticipate also via bicarbonate using product to it end the This are Despite submission We end clinical be approval the guidance FDA Triferic premixed on when We units clinics the June, Sterlite in helpful blood US, hospital the of passes acute dialysis machine. directly receive expected will commercializing in liquid the to approval in or the and QX it cartridges. dialysis the XXXX. FDA based containing of pre-mixed XXXX. infusion enables bicarbonate. arterial to Once based will
Europe. I’ll for this program we in our Europe, the to Triferic EMA designing we studies received that of fluid clinical later studies turn PD clinical Triferic the to over PD plan from initiate scientific are dosing year. this to financials. With to now We the clarify advice the study, in said, correct and In call for start further Regarding hope year. Triferic Tom
